284 results about "Infection disease" patented technology

The invention relates to an orthopedic postoperative drainage liquid infection risk identification method. Drainage liquid is regarded as system output jointly driven by postoperative local immune regulation and wound recovery; capturing a nonlinear time sequence curve; first-order derived trend modeling is carried out; abrupt change after the change rate is stable is analyzed; establishing a postoperative recovery normal path framework, and forming a standard recovery trend library by using drainage fluid dynamic parameters of non-infected cases; comparing the Euclidean offset degree and directional change between the drainage parameter behavior vector of the current patient and the standard trajectory; the change is converted into a visual recovery offset map, and infection prediction data is measured from a multi-day trend angle; constructing and identifying local abnormal signal aggregation; forming a framework of infection event transition to obtain clinical infection nodes of qualitative change caused by quantitative change; according to the method, early-stage accurate recognition can be realized, the intervention opportunity can be obviously advanced, single threshold misjudgment is avoided, the recognition accuracy and specificity are improved, the model adaptability is improved, and the recognition interpretability is enhanced.

The invention provides a bionic antibacterial peptide, a pharmaceutical composition, application of the bionic antibacterial peptide in preparation of antibacterial drugs and a design method of the bionic antibacterial peptide. A plurality of compounds are used for carrying out N-terminal modification on a polypeptide sequence consisting of 20 natural amino acids, so that a novel antibacterial peptide with a bionic function is generated, and the designed bionic antibacterial peptide is screened by adopting a method based on deep learning and experimental interaction. Compared with traditional drug screening, consumed time, manpower, material resources and financial resources are greatly reduced, the designed novel bionic antibacterial peptide has good biocompatibility, a functional group modified at the N end of the novel bionic antibacterial peptide can activate the self-assembly activity of polypeptide and help the polypeptide target a bacterial membrane, bacterial drug resistance is not likely to be caused, and the novel bionic antibacterial peptide has good application prospects. The drug-resistant bacteria can be effectively killed, the sterilization speed is higher, and potential and wide application prospects are achieved in clinical treatment of bacteria and drug-resistant bacteria infection diseases.

The invention discloses an application of phloretin in preparation of a medicine or a feed additive for treating or preventing swine envelope virus infection, the medicine is phloretin or oral liquid, granules, tablets and powder prepared from phloretin as an effective component and a solvent or an auxiliary material, and the use dosage is 2.5-10mg / kg of the body weight of a pig; or the phloretin is directly added into the feed, and the addition amount of the phloretin is 0.01-0.03% of the total weight of the pig feed. The phloretin or the composition containing the phloretin is used as a medicine or a feed additive, is high in safety and free of toxic and side effects, and has the effects of remarkably inhibiting replication of envelope viruses such as porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus and African swine fever virus and reducing the toxicity of the porcine envelope viruses; the defects of immune failure possibly caused by vaccination, virus variation caused by use of antiviral drugs and the like are overcome, the morbidity and mortality of the piglets infected with the swine envelope virus are effectively reduced, and the effect of preventing and treating or preventing the swine envelope virus infection diseases is achieved.

The invention relates to a nano-liposome preparation, which is characterized in that a liposome prepared from distearoyl phosphatidyl glycerol (DSPG), cholesterol and Biotin-PEG3000-cholesterol is used as a carrier, the surface of the nano-liposome preparation is modified with an ICAM-1 monoclonal antibody, and the nano-liposome preparation is loaded with an AIE photosensitizer and Nicodil. The nano-liposome prepared by the invention has targeting and responsive drug delivery to infected lesions, the enrichment of drugs at bacterial infected parts is improved, nano-system components can be cut by phospholipase in an infected microenvironment, responsive release of the drugs at the bacterial infected parts can be realized, and the treatment effect is improved. According to the invention, a hydrophobic shell layer and a hydrophilic core of the liposome are utilized, and hydrophobic NO donor molecules and a hydrophilic AIE photosensitizer are loaded at the same time, so that synergistic treatment of bacterial infection by a photodynamic therapy and a gas therapy is realized, and a better killing effect on drug-resistant bacteria is achieved.

The invention discloses an ebbuselenium derivative, a pharmaceutical composition and application of the ebbuselenium derivative. The ebbeselenium derivative provided by the invention has the characteristic of inhibiting PPK activity, reduces the polyphosphoric acid (polyP) level of bacteria, reduces the formation of biological membranes, reduces the athletic ability of the bacteria, reduces the generation of virulence factors, can also enhance the sensitivity of the bacteria to antibiotics, and can be used for preparing a medicine for preventing and treating the diseases, such as the diseases, the pests and the like. Therefore, the compound is used for preventing and treating bacterial infection diseases.

The invention relates to a model training method and a respiratory tract infection pathogen identification method and system, and the method comprises the steps: obtaining the clinical data of a respiratory tract infection pathogen; preprocessing the clinical data to obtain a training set; training a respiratory tract infection pathogen recognition model by using the training set to obtain the trained respiratory tract infection pathogen recognition model; wherein the trained respiratory tract infection pathogen identification model is used for identifying the respiratory tract infection pathogen based on the index detection data of the respiratory tract infection pathogen. Compared with the prior art, the method has the advantages of good recognition effect, low sampling requirement, high treatment efficiency and the like.

Systems and methods for selecting a treatment regimen for a particular patient are provided. The treatment regimen is selected using a first data store including a first plurality of patient records for a first plurality of patients, and a second data store including efficacy rates of a plurality of treatment regimens against a plurality of infections and infection-causing pathogens. The system, or a user of the system, identifies a first infection of the particular patient and a first treatment regimen to be prescribed to treat the first infection. A second plurality of patient records is generated by identifying, in the first plurality of patient records of the first data store, patient records associated with diagnosis or treatment of the first infection. The second plurality of patient records are appended with efficacy rates for the first infection from the second data store. Systems and methods of the present disclosure can use these appended records to generate a dynamic model configured to determine a likelihood estimation that the first treatment regimen is an appropriate treatment regimen to treat the first infection.

The invention provides a method for detecting the content of CIAV (chicken infectious anemia virus), which is characterized in that a conventional method for detecting the half-cell infection amount (TCID50) of CIAV by MDCC-MSB1 cells is improved, and whether the cells are infected with viruses or not is judged by an indirect immunofluorescence method. The method specifically relates to cell culture and passage, CIAV virus liquid dilution and inoculation, cell fixation, primary antibody and secondary antibody incubation, result determination and TCID50 calculation. The CIAV virus content detection only needs 4 days, and the implementation period is shorter than that of an existing method; meanwhile, whether the cells are infected or not is judged by an indirect immunofluorescence method, so that the problem of misjudgment caused by unobvious cytopathy is avoided, and the accuracy of virus content detection is further improved.

The utility model discloses a livestock and poultry transport vehicle capable of killing viruses, relates to the technical field of livestock and poultry transport vehicles, and aims to solve the problems that most of the existing livestock and poultry transport vehicles only have a conveying effect and a single function, livestock and poultry are infected with viruses in the transportation process and cannot be sterilized in time, and heavy loss is easily caused. A transport compartment body is arranged at the upper end of a pallet of the transport vehicle body, a feeding and discharging opening is formed in the front surface of the transport compartment body, and a sealing door for opening and closing the feeding and discharging opening is arranged in the feeding and discharging opening. The transport compartment comprises a transport compartment body and further comprises a transport cavity, the transport cavity is formed in the transport compartment body, a first partition plate dividing the transport cavity into independent spaces is arranged in the transport cavity, and a second partition plate is arranged on one side of the first partition plate; the rotating shafts are arranged on one side of one end of the first partition plate and one side of one end of the second partition plate, and the two rotating shafts are fixedly welded to the first partition plate and the second partition plate correspondingly.

The utility model provides a hatching egg storing and turning device, and belongs to the technical field of hatching egg storage. The device comprises a transition box and a storage box. Wherein the transition box is provided with a plurality of cavities, the cavities are communicated in sequence, one cavity is provided with an air inlet, the air inlet is communicated with the outside and used for air inflow, and the other cavity is internally provided with a delayed sterilization channel used for sterilizing germs in air; the storage box is communicated with one cavity of the transition box and used for providing sterilized air for the storage box, an air outlet is formed in the communication position, and the storage box is provided with an exhaust channel. According to the transition box provided by the utility model, air can be pretreated, and germs contained in the air can be killed, so that the content of the germs in the air entering the hatching egg accommodating bin is reduced, and the probability that hatching eggs are infected with the germs is reduced.

The present invention relates to a composition for preventing or treating virus infection diseases containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, inflammatory cells and inflammatory cytokines were found to decrease in the lungs of an influenza virus-infected animal model to which taurodeoxycholic acid or a pharmaceutically acceptable salt thereof was administered as an inflammasome inhibitor, and thus the inflammasome inhibitor containing taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in the composition for preventing or treating virus infection diseases.

The invention discloses a natural tobacco extract and application thereof in prevention and treatment of plant viruses, and belongs to the technical field of agricultural drugs and biology. A natural extract is obtained from tobacco leaves slightly infected with viruses, and experiments show that when the tobacco natural extract is sprayed on the plant leaves infected with the viruses, the immune defense capability of plants can be induced, propagation and replication of the viruses can be effectively inhibited, the disease resistance of the plants is enhanced, and the effect of preventing and treating the viruses is achieved. Therefore, the purpose of improving crop yield and quality is achieved. The natural tobacco extract can be used as an effective component of a plant antiviral agent, and a new direction is provided for research and development of the plant antiviral agent. The method for preventing and treating plant viruses by externally spraying the natural tobacco extract has the advantages of being environmentally friendly, non-toxic and harmless, is an ideal plant virus prevention and treatment technology, is simple and efficient, can keep high stability and practicability in field application, and meets the current requirements for ecological safety and sustainable development.

The invention relates to the technical field of bovine viral diarrhea virus detection, in particular to a bovine viral diarrhea virus multi-epitope fusion protein and application thereof, a coding gene of the bovine viral diarrhea virus multi-epitope fusion protein is a nucleotide sequence as shown in SEQ ID NO.5 and corresponds to an amino acid sequence as shown in SEQ ID NO.9, and the coding gene of the bovine viral diarrhea virus multi-epitope fusion protein is an amino acid sequence as shown in SEQ ID NO.9. The recombinant plasmid comprises a coding gene of the bovine viral diarrhea virus multi-epitope fusion protein. The bovine viral diarrhea virus monoclonal antibody is used as a coating antibody, and the bovine viral diarrhea virus multi-epitope fusion protein is used as a marker antigen, so that early infection cases can be found, and a detection result can be provided for health management of cattle herds in time, so that corresponding prevention and control or treatment measures can be taken in time, and the detection efficiency is improved. Different subtypes of BVDVs can be detected more widely, and the applicability to detection of different popular subtypes of BVDVs in different regions is improved.

The invention discloses application of salidroside in preparation of a preparation for resisting virus infection of macrobrachium rosenbergii, and relates to the field of antiviral application. The salidroside is injected into the macrobrachium rosenbergii infected with the DIV1 virus, so that the accumulative survival rate of the macrobrachium rosenbergii infected with the DIV1 virus can be remarkably increased, the replication capacity of the DIV1 virus is inhibited, and the relative expression quantity of antiviral genes is increased; the salidroside can be used as a medicine or a feed additive for preventing or treating antiviral infection of macrobrachium rosenbergii.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The thymus dependent lymphocyte antigen epitope peptide of the hepatitis B virus antigen is characterized in that the amino acid sequence of the epitope peptide comprises any one or more of the following: SPTVWLSVI; an LPLLPIFFCL (low-performance liquid chromatography- CPTVQASKL, and CPTVQASKL; an LPSDFFPSI (Liquefied Peptide The amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The application discloses a method for creating a new strain of Carassius auratus gibelii with resistance to Cyprinid herpesvirus 2 (CyHV2) infection, and the method is characterized in that a gene editing technology is used to target knockout gsdf-a a gene and gsdf-b a gene, and an experimental animal infection model of a homozygous knockout strain of the gene obtained by the technology is established. gsdf Results of the experimental animal infection model show that gsdf the CyHV2 infection resistance of the CyHV2 gene knockout Carassius auratus gibelii is significantly enhanced, the histopathological damage of the Carassius auratus gibelii after being infected with the virus is reduced, the expression of a virus protein ORF47 in liver tissue of the Carassius auratus gibelii is reduced, and the transcription level of a virus gene orf46r is significantly reduced. The new strain of Carassius auratus gibelii created by the method can avoid exogenous gene pollution, and has the advantages that the CyHV2 infection resistance of the Carassius auratus gibelii is significantly enhanced.

The application discloses an application of baicalin in treating coronavirus infectious diseases. The new application of baicalin is verified through in-vitro cell tests and mouse tests infected with human coronavirus HCoV-229E, the technical scheme is novel, and a curative effect test of baicalin in treating pneumonia caused by HCoV-229E virus infection is carried out, and the results show that baicalin has a certain inhibitory effect on HCoV-229E infected cells in vitro; baicalin shows good drug efficacy in lung index and inhibition rate of pneumonia mice infected with HCoV-229E virus, can reduce the virus load of lung tissue of pneumonia mice infected with HCoV-229E virus, increase the proportion of peripheral blood lymphocytes of mice, and reduce the content of IL-2, IL-10, TNF-alpha and IFN-beta in lung tissue of mice.

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

The invention provides a rabbit-source BCR sequence primer group based on high-throughput single cell V (D) J sequencing and application of the rabbit-source BCR sequence primer group. The primer group comprises a specific nested PCR (Polymerase Chain Reaction) primer pair (the sequence is as shown in SEQ ID NO.1-12) aiming at a rabbit BCR heavy chain (IgA / IgE / IgG / IgM) and a light chain (IgK / IgL). Through microfluid single-cell separation, nested PCR amplification and high-throughput sequencing, the naturally paired rabbit BCR full-length V (D) J sequence can be efficiently obtained. According to the rabbit-derived BCR sequence sequencing primer provided by the invention, B cell receptor library information of different tissue sources can be quickly and efficiently obtained. According to the method, paired antibody sequence information can be specifically obtained, B cell response diversity after rabbit immunization vaccine or pathogen infection can be better known, and important data support is provided for design, optimization, effect evaluation and the like of biological products.

The present application relates to the technical field of micro-grafting, and provides a Xinggongguo seedling micro-grafting device and method, wherein the Xinggongguo seedling micro-grafting device comprises a fixing frame, a supporting plate, a displacement assembly, a top shell, a clamping assembly and a cutting assembly; the supporting plate is fixedly installed on the fixing frame; the displacement assembly is installed inside the fixing frame and is used for adjusting the position of the seedling to be grafted; the top shell is rotatably installed on the top of the fixing frame; the clamping assembly is installed on the supporting plate and the displacement assembly and is used for fixing the positions of the seedling to be grafted and the stock; and the cutting assembly is installed on the supporting plate and is used for cutting grooves in the clamped seedling to be grafted and the stock. Through the above technical scheme, the problem of low grafting success rate caused by the high possibility of infection of pathogenic bacteria due to the phenomenon that the grooves are not flush when cutting the small stock and scion in the prior art is solved.

The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen and application, and belongs to the field of medical immunology and infectious pathology. The invention discloses thymus dependent lymphocyte antigen epitope peptide of hepatitis B virus antigen. The amino acid sequence of the epitope peptide comprises any one or more of SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL, SYVNVNMGL LATWVGSNL (Lattice, Attention, an RRMETTVNA (radio frequency identification tag); mAARVCCQL is used as a template; the amino acid sequence is an amino acid sequence obtained by removing or replacing a single amino acid of the amino acid sequence. The epitope peptide disclosed by the invention can be specifically combined with cytotoxic thymus dependent lymphocytes to stimulate the cytotoxic thymus dependent lymphocytes to activate, proliferate and differentiate, so that the immune effect of resisting the hepatitis B virus is exerted; the antigen peptides can be used for preparing therapeutic and prophylactic vaccines for hepatitis B virus infection, can also be used for preparing detection reagents for detecting hepatitis B virus specific cytotoxic thymus dependent lymphocytes, and have potential application value in prevention, treatment and diagnosis of hepatitis B.

The application discloses a kind of enveloped virus inactivation preparation based on medium-chain triglyceride and application thereof, the present application relates to the technical field of biological medicine external preparation, including active ingredient and auxiliary material: the active ingredient includes: high-purity medium-chain triglyceride (MCT), preferably octanoic acid (C8) and capric acid (C10) triglyceride mixture, purity ≥99%; The auxiliary material includes: food-grade antioxidant, for preventing oxidation of preparation, the content of food-grade antioxidant is 0.01-0.05%w / w, with medium-chain triglyceride as active ingredient, through the physical and chemical synergistic effect, enveloped virus is efficiently killed, for treating stubborn skin mucosa infection diseases (such as stubborn flat warts, herpes labialis, genital herpes, etc.) caused by human papillomavirus (HPV), herpes simplex virus (HSV-1 / HSV-2), varicella-zoster virus and other enveloped viruses.

Disclosed herein are compositions and methods useful for the prevention, treatment, reduction, or amelioration of various diseases, disorders, or conditions. Some aspects pertain to a pharmaceutical composition comprising 17-ethynyl-10R, 13S-dimethyl 2, 3, 4, 7, 8R, 9S, 10, 11, 12, 13, 14S, 15, 16, 17-hexadecahydro-1H-cyclopenta[a]phenanthrene-3R, 7R, 17S-triol, including solid states thereof. Also presented herein is the surprising discovery that exposing a subject to the compound and / or compositions disclosed herein can prevent, treat, reduce, or ameliorate a condition related to a subject previously infected with a virus.

A protective apparatus for use in medical and dental procedures to prevent exposure and exchange of harmful substances between an area isolated by the apparatus and the environment of use. The apparatus includes a physical shield, a vacuum barrier, and an adjustable support frame. The apparatus further includes a vacuum connector for connecting the apparatus to a vacuum source, a vacuum conduit for flow communicating with the air around the perimeter of the physical shield such that the vacuum source draws air along with solid and liquid matter entrained in the air into the vacuum conduit, and a plurality of vacuum apertures located along the vacuum conduit for communicating the vacuum source with the air. The apparatus provides protection for persons in proximity to a source of harmful substances such as aerosols derived from patients infected with viruses or the like and more in particular corona viruses.

The invention provides a respiratory tract infection pathogen antibody spectrum detection method and a respiratory tract infection pathogen antibody spectrum detection system, and relates to the technical field of biomass energy industries. If yes, performing gain dynamic adjustment based on the instrument stability dynamic evaluation result and the data quality parameters, performing antibody spectrum detection by using the instrument subjected to gain dynamic adjustment, and if the instrument stability dynamic evaluation result is a normal instrument, directly performing antibody spectrum detection by using the instrument; performing flow velocity rationality dynamic evaluation based on the flux efficiency demand and the sample core parameter, and executing liquid flow dynamic adjustment based on the liquid flow quality control parameter according to a flow velocity rationality dynamic evaluation result; and dynamically generating the antibody spectrum of the respiratory tract infection pathogen based on the microsphere coding information and the fluorescence intensity signal output by the flow cytometry after the liquid flow dynamic regulation.

The invention belongs to the technical field of nano diagnosis and treatment agents, and particularly relates to a preparation method and application of a multi-field response type nano diagnosis and treatment agent, the preparation method of the multi-field response type nano diagnosis and treatment agent comprises a core layer, a middle shell layer and an outer wrapping layer, the core layer is DCNPs, the middle shell layer is Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs, and the outer wrapping layer is an Nd0. 03Fe0. 97Se2 wrapping the surface of the DCNPs. And the outer coating layer is HA which is coated on the outer side of the Nd < 0.03 > Fe < 0.97 > Se < 2 >. According to the invention, a multi-mode therapy of membrane structure defect induction-oxidative stress-metabolism interference-energy blocking can be realized, the mucous barrier penetrating ability is good, the retention ability of DNH in a pulmonary infection focus is improved, efficient drug delivery is realized, real-time NIR-II diagnosis can be assisted, and the application prospect is wide. The efficient treatment of lung bacterial infection diseases is realized.

The present invention discloses for the first time that the Chinese herbal medicine baicalin has the effect of resisting largemouth bass rhabdovirus, and baicalin exerts the antiviral effect by inhibiting the adsorption of largemouth bass rhabdovirus; the baicalin can significantly improve the survival rate of largemouth bass fry infected with largemouth bass rhabdovirus, and has the preventive and therapeutic effects on the infected virus; and the raw materials of baicalin are abundant and cheap, the preparation process is simple and the cost is low, and the baicalin has good development and application prospects in the preparation of anti-largemouth bass rhabdovirus drugs.

This invention relates to the field of biotechnology, and in particular to an antigenic epitope peptide, product, and application for detecting antibodies produced by porcine deltacoronavirus infection. This invention identified short peptide epitopes in PDCoV longitudinal challenge serum samples, obtaining 12 short peptides, which were then prepared into a porcine deltacoronavirus antibody detection kit. Finally, six field serum samples were selected for antibody detection, and the effectiveness was verified using a virus neutralization experiment. The results showed that the porcine deltacoronavirus antibody detection kit provided by this invention is effective. Furthermore, the porcine deltacoronavirus antibody detection kit provided by this invention, as a novel detection method, improves sensitivity and specificity while simultaneously providing multiple detection results, namely, determining whether viral infection has occurred, identifying the stage of infection, and achieving DIVA (Differentiation, Infection, and Variability) analysis.

The invention relates to the field of bioengineering, in particular to a recombinant human herpes simplex virus as well as a construction method and application thereof. The recombinant human herpes simplex virus lacks US1, US2, US3, US4 and US5 virulence genes at the same time. The construction method comprises the following steps: constructing a donor plasmid, and constructing a cleavage plasmid; transfecting cells with the cleavage plasmids and the donor plasmids in proportion; and after the transfected cells are incubated, infecting with an HSV-1 virus, purifying, and verifying to obtain the recombinant virus. The donor plasmid constructed by the invention retains non-coding regions among US1, US2, US3, US4 and US5 genes, also retains initiation codons and termination codons of the US1, US2, US3, US4 and US5 genes, is added with a fluorescent tag sequence, and can knock out five virulence genes of HSV-1US1-US2-US3-US4-US5 at the same time. The neutralizing antibody titer result of the recombinant human herpes simplex virus is the same as that of a wild type, and a foundation is laid for vaccine preparation.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.